Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.

Cancers (Basel) · 2020 · PMC7139837 · PMID 32110977

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Regarding the most common safety events, mFOLFIRINOX strategy showed a trend towards reduced risk for a G3–G5 AE (RR 0.80, 95% CI 0.62–1.02), and non-statisticallysignificant differences were associated with anemia, diarrhea, fatigue, neuropathy, and neutropenia.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.